ecrin-mdr-crcClinical2021Solid tumorNeoplasm MetastasisSquamous Cell Carcinoma of Head and NeckCarcinomaNSCLCCarcinoma, Non-Small-Cell LungLung cancerAdvanced Solid TumorColorectal NeoplasmsRefractory TumorMetastatic TumorNeoplasmsSquamous Cell Carcinoma Of Head And NeckNeoplasm MetastasisSolid TumorCarcinomaLung CancerNsclcColorectal NeoplasmsAdvanced Solid TumorCarcinoma, Non-small-cell LungRefractory TumorMetastatic TumorNeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2393891United States11NK cellsAntibodySNK01SCCHNIgG1EGFRADCPNatural killer cellEGFR+EGFR PositiveCD16AMetastaticADCCAFM24ECRIN MDRActive, not recruitingfalseSafety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing CancersThis is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.2021-11-152393891NCT05099549